Project Grant R43CA250841

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Assayquant Technologies, Inc. provides $1,093,104 to develop and commercialize a suite of biosensor peptides for the quantitative, high-throughput measurement of oncogenic protein kinases in cell and tissue samples. The key products to be developed and validated under this 2-year award include: Lysate-compatible sensor peptides for measuring activity of mitogen-activated protein kinases (MAPKs)...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel high-throughput screening (HTS) assay platform that can directly monitor drug-induced changes in RNA levels of dengue and influenza viruses. The $300,000 award to Lucerna Inc., a minority-owned small disadvantaged business, will fund the creation of this HTS-compatible cell-based reporter system to...

This National Science Foundation (NSF) Project Grant, awarded under the Biological Sciences program (CFDA 47.074), provides $750,000 to Stanford University to develop new technologies for studying RNA, the essential molecules that carry genetic information and play crucial roles in cell functions. The key products and services to be delivered under this 3-year award include: Creating non-destructive methods to directly study RNA localization and interactions within living cells, achieving...

The National Cancer Institute (NCI) awarded a $990,771 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Binary Genomics, Inc., a minority-owned for-profit organization located in Madison, CT. The project aims to build clinical data supporting the use of Binary Genomics' circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapies. The technology leverages epigenetic features to broadly detect ctDNA without...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $607,250 to the Scripps Research Institute in La Jolla, CA to investigate the role of DNA polymerase theta (POLQ) in repairing replication-associated DNA double-strand breaks and exploiting this as a potential cancer treatment strategy. The award period runs from September 1, 2024 to August 31, 2029. The key objectives of this research project are to...

The National Cancer Institute (NCI) awarded a $356,850 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to Oregon Health & Science University (OHSU) to characterize the pre-analytical steps involved in blood and bone marrow biopsy sample handling and storage/retrieval for functional assay reporting. The project aims to establish pre-analytical sample processing guidelines to enable maximal reproducibility for functional testing outcomes, including high throughput-drug...

The National Cancer Institute (NCI) awarded a $440,287 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to GE Medical Systems Information Technologies, Inc. to establish a simplified and accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This aims to democratize biobanking capabilities for lower resource institutes. The project, titled "A Novel Multi-Analyte Approach to Democratize Cancer...